Literature DB >> 9612114

Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.

J Thum1, L Caspary, A Creutzig, K Alexander.   

Abstract

BACKGROUND: Disturbed skin microcirculation in patients with peripheral arterial occlusive disease (PAOD) might be affected by prostaglandin E1 (PGE1). The purpose of this study was to investigate local skin perfusion at the forefoot and toe of PAOD patients during different modes of administration of PGE1. PATIENTS AND METHODS: In 17 patients with severe PAOD local intradermal haemoglobin oxygen saturation (SHB) and dermal vascular reserve capacity, transcutaneous oxygen pressure (tcPO2) and laser Doppler flux (LDF) were determined during intra-arterial (1.5 ng/kg body weight/min) and intravenous (6 ng/kg body weight/min) infusion of PGE1.
RESULTS: SHB significantly increased at both locations during intravenous PGE1; intra-arterial administration significantly increased SHB in the skin of the forefoot only. Reserve capacity increased during intravenous administration and was markedly reduced during intra-arterial infusion. No significant changes were found regarding tcPO2 and LDF.
CONCLUSIONS: These data suggest different therapeutic mechanisms for intra-arterial and intravenous administered of PGE1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9612114

Source DB:  PubMed          Journal:  Vasa        ISSN: 0301-1526            Impact factor:   1.961


  2 in total

1.  Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.

Authors:  Ying Cheng; Miao Liu; Huijing Hu; Daozhou Liu; Siyuan Zhou
Journal:  AAPS PharmSciTech       Date:  2015-07-21       Impact factor: 3.246

2.  Anticoagulative strategies in reconstructive surgery--clinical significance and applicability.

Authors:  Andreas Jokuszies; Christian Herold; Andreas D Niederbichler; Peter M Vogt
Journal:  Ger Med Sci       Date:  2012-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.